KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Clinical Benefit

Conditions

Non-Small Cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer
Non-Squamous Non-Small Cell Neoplasm of Lung
KEAP1 Gene Mutation
NRF2 Gene Mutation
NFE2L2 Gene Mutation

Interventions

DRUG: Telaglenastat
DRUG: Carboplatin Chemotherapy
DRUG: Pemetrexed Chemotherapy
BIOLOGICAL: Pembrolizumab Immunotherapy
DRUG: Placebo
DIETARY_SUPPLEMENT: Folic acid 400 -1000 μg
DIETARY_SUPPLEMENT: Vitamin B12 1000 μg
DRUG: Dexamethasone 4 mg

Sponsor

Calithera Biosciences, Inc